Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous injection use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and to provide anticoagulation during hemodialysis and surgical procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with robust quality assurance and regulatory support for patient care.

Ledraxen, a low molecular weight heparin, is used in clinical settings that require inhibition of clot formation. - Deep vein thrombosis (DVT): prevents clot extension and reduces recurrence. - Pulmonary embolism (PE): treats existing emboli and prevents new events. - Hemodialysis anticoagulation: maintains circuit patency during dialysis sessions. - Surgical thromboprophylaxis: reduces risk of postoperative thromboembolic complications.

Enoxaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site bruising or pain - Minor bleeding such as epistaxis or gum bleeding - Hematuria - Nausea - Elevated liver enzymes

Serious or Rare Side Effects: - Major hemorrhage (intracranial or gastrointestinal) - Thrombocytopenia (including heparin‑induced thrombocytopenia) - Allergic reactions (anaphylaxis, urticaria) - Spinal or epidural hematoma with neuraxial procedures

Prior to initiating Ledraxen therapy, clinicians should evaluate several safety considerations to minimize risk. - Renal function: assess creatinine clearance and adjust dose in severe impairment. - Platelet count: monitor for thrombocytopenia, especially within the first two weeks. - Concomitant anticoagulants: avoid or use caution with other anticoagulant or antiplatelet drugs. - Pregnancy: use only if potential benefit outweighs risk, as safety data are limited. - Surgery or invasive procedures: discontinue before neuraxial anesthesia to reduce hematoma risk. - Store below 25°C: keep in original packaging, protect from moisture and light.

Enoxaparin can interact with other medicines, altering anticoagulant effect or bleeding risk.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, direct thrombin inhibitors) may cause uncontrolled bleeding. - Neuraxial anesthesia or spinal puncture while on therapy increases risk of spinal hematoma. - Heparin‑induced thrombocytopenia history: avoid due to cross‑reactivity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents (aspirin, clopidogrel) may enhance bleeding. - Selective serotonin reuptake inhibitors (SSRIs) can increase risk of gastrointestinal bleeding. - ACE inhibitors or diuretics may affect renal clearance, requiring dose review.